发明名称 Method of dosing and use of soft anticholinergic esters
摘要 A method of treating hyperhidrosis in a mammalian subject comprising: a) providing a composition comprising a pharmaceutically acceptable vehicle and from about 1.0% to about 25% of a compound having the formula:; and b) topically administering the composition to skin of an area of a mammalian subject suffering from hyperhidosis, before bedtime, such that, compared to untreated, baseline conditions, sweat production is reduced by at least about 25% for at least about six (6) hours.
申请公布号 US9492429(B2) 申请公布日期 2016.11.15
申请号 US201514941183 申请日期 2015.11.13
申请人 BODOR LABORATORIES, INC. 发明人 Bodor Nicholas S.;Angulo David
分类号 A61K8/00;A61K31/40;A61K8/49;A61Q15/00;A61K9/00;A61K47/10;A61K8/41;A61K31/4015;A61K31/14;A61K31/205 主分类号 A61K8/00
代理机构 Dentons US LLP 代理人 Dentons US LLP
主权项 1. A method of treating hyperhidrosis in a mammalian subject, said method comprising topically administering a composition comprising a pharmaceutically acceptable vehicle and from about 1.0% to about 25% of a compound having the formula:wherein R is methyl or ethyl, said compound having the R stereoisomeric configuration at the 2 position and the R or RS steroisomeric configuration at the 1′ and 3′ position, said compound being selected from the group consisting of: (iii) (2R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(methoxycarbonylmethyl)-1-methylpyrrolidinium bromide; (iv) (2R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; (v) (2R,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(methoxycarbonylmethyl)-1-methylpyrrolidinium bromide; and (vii) (2R,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;or being a mixture thereof; to skin of an area of a mammalian subject suffering from hyperhidosis, before bedtime, such that, compared to untreated, baseline conditions, sweat production is reduced by at least about 25% for at least about six (6) hours; and such that sweat production is reduced by an amount substantially equivalent to an amount that sweat production is reduced as compared to untreated, baseline conditions, following administration of a composition comprising the same concentration of glycopyrrolate, and with an improved safety profile compared to topical glycopyrrolate.
地址 Miami FL US
您可能感兴趣的专利